Browse studies, page 109
Page 109 of 1,286, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Moxifloxacin in the Treatment of Elderly Patients with Community Acquired Pneumonia Pharmaceutical and Clinical Research, 2011
- Rickettsia typhi Infection with Interstitial Pneumonia in a Traveler Treated with Moxifloxacin Journal of Clinical Microbiology, 2010
- Cure of Q fever pneumonia with moxifloxacin: Case report Scandinavian Journal of Infectious Diseases, 2005
- Successful treatment of Legionella pneumonia with moxifloxacin in a hemodialysis patient PubMed, 2009
- Clinical observation of moxifloxacin therapy for of mycoplasma pneumonia Xiandai yufang yixue, 2011
- Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae International Journal of Antimicrobial Agents, 2000
- Therapeutic effect of Moxifloxacin on community acquired pneumonia Shiyong yaowu yu linchuang, 2007
- Effect of moxifloxacin on severe community acquired pneumonia Zhongguo redai yixue, 2012
- Application of sequential therapy of moxifloxacin in acute pneumonia Clinical Medicine, 2010
- The action of moxifloxacin in the elderly community-acquired pneumonia Journal of Clinical Pulmonary Medicine, 2010
- Clinical efficacy of moxifloxacin on mycoplasma pneumonia of adults Shiyong yaowu yu linchuang, 2013
- Efficacy and safety of moxifloxacin on community acquired pneumonia Shiyong yaowu yu linchuang, 2009
- Role of moxifloxacin in the treatment of community-acquired pneumonia PubMed, 2004
- Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia Antimicrobial Agents and Chemotherapy, 2004
- Moxifloxacin for Community-Acquired Pneumonia Antimicrobial Agents and Chemotherapy, 2002
- A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia ClinicalTrials.gov · COMPLETED, 2017
- A Randomized Clinical Trial of Oral Clarithromycin in Community-acquired Pneumonia to Attenuate Inflammatory Responses and Improve Outcomes: the ACCESS Clinical Trial ClinicalTrials.gov · COMPLETED, 2023
- A Phase 3B Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial To Evaluate The Efficacy and Safety Of Azithromycin SR (Microspheres Formulation) Versus Moxifloxacin For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB) ClinicalTrials.gov · COMPLETED, 2008
- Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients ClinicalTrials.gov · COMPLETED, 2012
- A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults ClinicalTrials.gov · COMPLETED, 2017
- A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia ClinicalTrials.gov · COMPLETED, 2017
- Prospective, Doubleblind, Randomized Multicenter Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia ClinicalTrials.gov · TERMINATED, 2011
- Prospective, Multi-center, Randomized, Non-blind Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Sulbactam/Ampicillin in the Treatment of Pulmonary Abscess and Aspiration Pneumonia ClinicalTrials.gov · COMPLETED, 2005
- A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia ClinicalTrials.gov · COMPLETED, 2018
- A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With Community-Acquired Pneumonia ClinicalTrials.gov · COMPLETED, 2013
- A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia ClinicalTrials.gov · COMPLETED, 2018
- A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP) ClinicalTrials.gov · COMPLETED, 2024
- A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia ClinicalTrials.gov · COMPLETED, 2015
- A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia ClinicalTrials.gov · COMPLETED, 2014
- Clinical efficacy of moxifloxacin in the treatment of Mycoplasma pneumonia Zhongguo kangganran hualiao zazhi, 2010
- Analysis of moxifloxacin in the treatment of 253 cases of stroke-associated pneumonia Zhongguo kangganran hualiao zazhi, 2011
- A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia Infection, 2007
- Nontuberculous Mycobacterial Pneumonia Caused by Mycobacterium immunogenum: A Case Report and Literature Review Infection and Drug Resistance, 2025
- Diagnosis of Tropheryma Whipplei pneumonia in an immunnocompromised Lymphoma patient Using Metagenomic Next Generation Sequencing: A Case Report Journal of Infection and Chemotherapy, 2025
- Community-acquired pneumonia associated with influenza co-infection caused by fusobacterium necrophorum: a case report and literature review BMC Infectious Diseases, 2025
- Case Report: Refractory Mycoplasma pneumoniae pneumonia complicated by pulmonary embolism and infarction in a child Frontiers in Pediatrics, 2025
- Clinical analysis of Moxifloxacin in treatment of acquired pneumonia Medical Innovation of China, 2012
- Efficacy of moxifloxacin in treatment of stroke-associated pneumonia in the elderly Zhongguo yiyuan ganranxue zazhi, 2012
- 2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study Open Forum Infectious Diseases, 2018
- Differences in efficacy of piperacillin sulbactam sodium and moxifloxacin in community-acquired pneumonia Guoji yiyao weisheng daobao, 2013
- Comparative Efficacy of Kanamycin, Enrofloxacin, Moxifloxacin and Cefoperazone for the Treatment of Pneumonia in Buffaloes Journal of Animal Research, 2018
- 663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials Open Forum Infectious Diseases, 2019
- 684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results Open Forum Infectious Diseases, 2019
- 699. Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results Open Forum Infectious Diseases, 2019
- 2232. A Global Phase 3 Study of Delafloxacin (DLX) Compared with Moxifloxacin (MOX) in Patients with Community-acquired Bacterial Pneumonia (CABP) Open Forum Infectious Diseases, 2019
- In community-acquired bacterial pneumonia, lefamulin was noninferior to moxifloxacin at 96 h after the first dose Annals of Internal Medicine, 2020
- Serum metabolite profiles as potential biochemical markers in young adults with community-acquired pneumonia cured by moxifloxacin therapy Scientific Reports, 2020
- Topological Indices of Antibiotic Drugs used in Pneumonia Treatment with their QSPR Analysis and M-polynomial Asian Journal of Chemical Sciences, 2023
- Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection Clinical drug investigation, 2021
- Epileptic Seizure after Use of Moxifloxacin in Man with Legionella longbeachae Pneumonia Emerging Infectious Diseases, 2020
- Validated spectrofluorimetric assay of two co-administered drug mixtures containing hydroxychloroquine with either moxifloxacin or ofloxacin as a drug regimen for hospital-acquired pneumonia in covid-19 patients Luminescence (Chichester, England Print), 2023
- Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials Open Forum Infectious Diseases, 2020
- Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials Open Forum Infectious Diseases, 2020
- Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study Open Forum Infectious Diseases, 2021
- P-618. Pooled Microbiological Outcomes from the Phase 3, Randomized OPTIC and OPTIC-2 Trials of Omadacycline vs Moxifloxacin in Community-acquired Bacterial Pneumonia Open Forum Infectious Diseases, 2026
- Clinical and laboratory features of pediatric Mycoplasma pneumoniae Pneumonia with viral versus bacterial co-infection Italian journal of pediatrics, 2026
- Co-Infection of Chlamydia psittaci and Methicillin-Resistant Staphylococcus aureus in Community-Acquired Pneumonia - A Case Report Infection and drug resistance, 2026
- Clinical Characteristics of 40 Cases of Chlamydia Psittaci Pneumonia Confirmed by Metagenomic Next-Generation Sequencing Infection and drug resistance, 2026
- Antibiotic and antiviral prescribing patterns among hospitalised patients with COVID-19 pneumonia in Mongolia: a real-world descriptive retrospective study Journal of pharmaceutical policy and practice, 2026
- Clinical characteristics of hospitalized children with mycoplasma pneumoniae pneumonia in Chinese tertiary hospitals during the 2023-2024 post-pandemic period Frontiers in cellular and infection microbiology, 2026
- Spinal Mucormycosis Following a Traditional Cupping Procedure in a Diabetic Patient: A Rare Case Report from Somalia International medical case reports journal, 2026
- A case report of relapsing organizing pneumonia in rheumatoid arthritis with literature review Medicine, 2026
- Eco-friendly approach for spectrofluorimetric determination of moxifloxacin in pharmaceutical formulations and biological samples using deep eutectic solvents BMC chemistry, 2026
- Case Report: Metastatic right ventricular tumor and pulmonary embolism from cervical cancer post COVID-19 infection Frontiers in immunology, 2026
- Chlamydia Abortus-Induced Pneumonia with Psychiatric Symptoms and Pneumomediastinum: A Case Report Infection and drug resistance, 2025
- A case of Nocardia asiatica pneumonia: Relapse caused by trimethoprim-sulfamethoxazole treatment nonadherence IDCases, 2026
- Pulmonary Mycobacterium fortuitum Infection Associated With Achalasia Treated With Peroral Endoscopic Myotomy Alone: A Case Report Respirology case reports, 2026
- Type 2 diabetes patient infected by soil-derived Legionella Longbeachae in China: A case report IDCases, 2026
- Clinical experience with fluoroquinolones for treatment of severe Chlamydia psittaci pneumonia with invasive mechanical ventilation in ICU: a retrospective study Frontiers in medicine, 2025
- Antimicrobial Susceptibility and Distribution Characteristics of Mycoplasma pneumoniae Isolates in Beijing, China, from 2017 to 2025 Pharmaceuticals (Basel, Switzerland), 2026
- Diagnosis and management of acute eosinophilic pneumonia masquerading as malignancy and community-acquired pneumonia in an elderly male: a case report AME case reports, 2026
- Diagnostic Pitfall: Prolonged COVID-19 Presenting as Organising Pneumonia in a Rituximab-Treated Patient with Rheumatoid Arthritis Mediterranean journal of rheumatology, 2026
- Streptococcus pneumoniae invasive and bronchoalveolar lavage isolates in adult patients in Türkiye (2019-2025): serotype distribution, antibiotic resistance, and serotype coverage of pneumococcal vaccine International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026
- Community-acquired Escherichia coli pneumonia: clinical, radiological, laboratory, and prognostic characteristics in a retrospective single-center study Annals of Saudi medicine, 2026
- Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018
- Eradication of Mycoplasma pneumoniae biofilm towers by treatment with hydrogen peroxide or antibiotic combinations acting synergistically PloS one, 2025
- Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis The Journal of infection, 2004
- Concentrations of moxifloxacin in serum and synovial fluid, and ex vivo bactericidal activity against arthritis-causing pathogens Diagnostic microbiology and infectious disease, 2004
- In vitro activity of BAY 12-8039, a new 8-methoxyquinolone Chemotherapy, 1996
- Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone Journal of chemotherapy (Florence, Italy), 2004
- The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia Respiratory medicine, 2001
- Q Fever pneumonia: are clarithromycin and moxifloxacin alternative treatments only? The American journal of tropical medicine and hygiene, 2005
- Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis JAMA ophthalmology, 2013
- Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model Current eye research, 2013
- Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS. BMC anesthesiology, 2017
- Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales The Journal of antimicrobial chemotherapy, 2001
- Mycoplasma pneumoniae infection in hospitalized adult patients with community-acquired pneumonia in China Journal of infection in developing countries, 2014
- Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect The Journal of antimicrobial chemotherapy, 2008
- Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022
- Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis Advances in therapy, 2011
- Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group Respiratory medicine, 2000
- Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases Nature structural & molecular biology, 2009
- Effects of subinhibitory concentrations of moxifloxacin in an in-vitro dynamic model Journal of chemotherapy (Florence, Italy), 2000
- Outbreak of mycoplasmal round pneumonia in an adult population: A case series The clinical respiratory journal, 2018
- Clinical characteristics and outcomes of acute respiratory distress syndrome caused by severe Chlamydia psittaci pneumonia Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2022
- The differential diagnosis of pneumonia in two patients infected by atypical pathogens Future microbiology, 2021
- Calculation of composite recovery time: a new pharmacodynamic parameter The Journal of antimicrobial chemotherapy, 2002
- Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2006
- Ocular manifestations of mycoplasma-induced rash and mucositis Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2020
- In vitro activity of moxifloxacin against respiratory pathogens in Latin America Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2002
